___

• 1. Blaustein A. Blaustein pathology of the female genital tract. Fourth edition Springer Verlag. New York 439-486, 1999.
• 2. Comoel et al. Bcl-2 expression in normal endometrium during the menstrual cycle. Am J Pathol 144(6): 1195-1202, 1994.
• 3. Hockenbery DM, Nunez G, Milliman C et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature; 348: 334-346, 1990.
• 4. Hockenbery DM, Zutter M, Hickey W et al. Bcl-2 protein is topograpically restricted in tissues characterized by apoptotic cell death. Proc. Nat Acad. Sci. USA; 88: 6961-6965, 1991.
• 5. Pezzela F, Tse AGD, Cordell JL et al. Expression of Bcl-2 oncogene protein is not specific for the 14,18 choromosomal translocation Am J Pathol; 137(2): 225-232, 1990.
• 6. Monaghan et al. Ultrastructural localization of Bcl-2 protein J Histochem: Cytochem. 10(12): 1819- 1825, 1992.
• 7. Le Brun DP, Warnke RA, Clearly ML. Expression of Bcl-2 in fetal tissues suggests a role in morphogenesis Am. J. Pathol; 169: 431-437, 1993.
• 8. Lu Long Ql, Poulsorn R, Wang L, Hanby AM. Bcl-Expression in adult and embryonic non haemotopoietic tissues J Pathol; 169: 431-437, 1993.
• 9. Zeng W, Cao P, Zheng M et al. P53 over-expression and Bcl-2 persistence in endometrial carcinoma: Comparison of papillary, serous and endometrioid subtypes. Gynecol Oncol; 61: 167-174, 1996.
• 10. Rajkumar T, Rajan S, Baruch RK et al. Prognostic significance of Bcl-2 and P53 protein expression in stage IIB and IIIB squamous cell carcinoma of the cervix Eur J Gynaecol Oncol. 19(6): 556-60, 1998.
• 11. Tjalma W, De Cuyper E, Weyler J et al. Expression of Bcl-2 in invasive and in situ carcinoma of the uterine cervix; Am J Obstet Gynecol; 178 (1 pt 1): 133-7, 1998.
• 12. Tjalma W, Van Marck E, De Rooter C et al. Prognostic value of Bcl-2 expression in patients with operable carcinoma of the uterine cervix J Clin Pathol; 50(1): 33-6, 1997.
• 13. Kokawa S, Shikone T, Otani T, Naknof. Apoptosis and the expression of Bax and Bcl-2 in squamous cell carcinoma and adenocarcinoma of the uterine cervix. Cancer, 85(8): 1799-809, 1999.
• 14. Harima Y, Nagata K, Harima K et al. Bax and bcl-expressions predict response to radiotherapy in human cervical cancer. J Cancer Res Clin Oncol. 124 (9): 503- 510, 1998.
• 15. Pillai MR, Jayaprakash PG, Nair MK. Bcl-2 immuno reactivity but not p53 accumulation associated with tumor response to radiotherapy in cervical carcinoma J Cancer Res Clin Oncol; 125(1): 55-60, 1999.
• 16. Crawford RA et al. Prognostic significance of the Bcl-2 apoptotic family of proteins in primary and recurrent cervical cancer. Br J Cancer. 78(2): 210-214, 1998.
• 17. Waggoner SF, Baunoch DA, Anderson SA et al. Bcl-2 protein expression associated with resistance to apoptosis in clear cell adenocarcinomas of the vagina and cervix expressing wild type p53. Am Surg Oncol, 5(6): 544-547, 1998.
• 18. McCluggage GI, McBride H, Maxwell P, Bhaurcha N. Immunohistochemical detection of P53 and Bcl-2 proteins in neoplastic and non-neoplastic endocervical glandular lesions. Int J Gynecol Pathol, 16(1): 22-7, 1997.
• 19. Dellas A et al. Investigation of the Bcl-2 and C myc expression in relationship to the KI-367 gene grown in cervical intraepithelial neoplasia. Int J Gynecol Pathol. 16 (3): 212-218, 1997.
• 20. Cooper K, Haffajen Z, Taylor L. Bcl-2 immunoreactivity, human papillomavirus DNA, and cervical intraepithelial neoplasia. Mod Pathol. 12(6): 612-617, 1999.